mCRPC Master

Применение для управления метастатическим кастрации устойчивостью рака простаты

Over the last 5 years, the number of therapeutic options for men with metastatic castrate-resistant prostate cancer (mCRPC) has increased exponentially. The optimal sequence in which to administer these therapies is a source of confusion for many healthcare providers who treat patients with mCRPC. Several organizations including the American Urological Association and the National Comprehensive Cancer Network have established guidelines for the treatment of men with mCRPC. These guidelines often differ in their recommendations and may even contradict expert opinion. Unfortunately, none of these sets of guidelines address bone health, serum lab testing, or imaging.

mCRPC MasterTM offers a solution. mCRPC MasterTM integrates current guidelines and expert opinion for management of mCRPC along with guidelines for maintaining bone health as well as recommendations for serum lab testing and imaging in a simple, interactive platform for mobile devices Android smartphones.

Healthcare providers are prompted to enter patient clinical data into the application, which then determines and displays the appropriate treatment options, recommendations for bone health, lab tests and imaging studies. This information can be viewed on the device or emailed to the provider or patient for printing or importation into an electronic health record. No sensitive patient information permanently resides in the application or on the mobile device.

As new developments in the care of mCRPC patient are reported the application will be updated within days of publication, rather than months. This will allow healthcare providers to provide the most up to date and comprehensive care for their patients with mCRPC possible.